Evidence map›Paper›PMID 35697891›Full record

ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2022

Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.

Fatemeh Nemati Shahri, Ahdieh Izanloo, Mohammad Ali Sheikh Beig Goharrizi, Ailar Jamali, Hanieh Bagheri, Afsaneh Hjimohammadi, Abdollah Ardebili

Abstract read
PubMed Publisher
In one paragraph

Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Enzyme Production and Inhibitory Potential ofAntibiotics (Basel, Switzerland) · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatemeh Nemati ShahriInfectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Ahdieh IzanlooDepartment of Biology, Faculty of Sciences, Golestan University, Gorgan, Iran.
Mohammad Ali Sheikh Beig GoharriziAtherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ailar JamaliInfectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Hanieh BagheriInfectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Afsaneh HjimohammadiInfectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Abdollah ArdebiliInfectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran. ardebili_abdollah57@yahoo.com.ORCID http://orcid.org/0000-0003-2386-8366

Funding

Golestan University of Medical Sciences 110212
6 · The paper itself

Abstract

Pseudomonas aeruginosa is an important nosocomial pathogen with a capacity of resistance to multiple antibiotics and production of various extracellular and cell-associated virulence factors that clearly contribute to its pathogenicity. The objective of this study was to investigate the antibiotic susceptibility, virulence factors, and clonal relationship among clinical isolates of P. aeruginosa. Different clinical specimens from hospitalized patients were investigated for P. aeruginosa. Susceptibility of the isolates was evaluated by disc diffusion and broth microdilution methods, as described by the Clinical and Laboratory Standards Institute (CLSI) guideline. A total of 97 P. aeruginosa isolates were recovered from clinical specimens. The percentage of isolates resistant to antimicrobials was imipenem 25.77%, meropenem 15.46%, gentamicin 16.49%, tobramycin 15.46%, amikacin 16.49%, ciprofloxacin 20.61%, levofloxacin 24.74, ceftazidime 20.61%, piperacillin 15.46%, piperacillin/tazobactam 12.37%, colistin 9.27%, and polymyxin B 11.34%. Of isolates, 87.62% possessed β-hemolytic activity, 78.35% lecithinase, 59.8% elastase, 37.11% DNase, and 28.86% twitching motility. The frequency of virulence genes in isolates was lasB 82.47%, plcH 82.47%, exoA 58.76%, exoS 56.7%, and pilA 10.3%. ERIC-PCR typing clustered P. aeruginosa isolates to 19 common types (CT1-CT19) containing isolates from different hospitals and 43 single types (ST1-ST43). Colistin and polymyxin B were the most effective agents against the majority of P. aeruginosa isolates, emphasizing the effort to maintain their antibacterial activity as last-line therapy. The frequency of some virulence factors and genes was noticeably high, which is alarming. In addition, more effective strategies and surveillance are necessary to confine and prevent the inter-hospital and/or intra-hospital dissemination of P. aeruginosa between therapeutic centers.

Indexed as

Pseudomonas aeruginosaPseudomonas InfectionsAmikacinAnti-Bacterial AgentsCeftazidimeCiprofloxacinColistinDeoxyribonucleasesDrug Resistance, BacterialGenotypeGentamicinsHumansImipenemIranLevofloxacinMeropenemAmikacinAnti-Bacterial AgentsCeftazidimeCiprofloxacinColistinDeoxyribonucleasesGentamicinsImipenemLevofloxacinMeropenemPancreatic ElastasePhospholipasesPiperacillinPiperacillin, Tazobactam Drug CombinationPolymyxin BTobramycinVirulence FactorsAntibiotic resistanceERIC-PCRPCR amplificationPseudomonas aeruginosaVirulence factors

Identifiers

PMID35697891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.